All the Active Ingredient Drugs
Monoclonal Antibody. Atezolizumab 1,200 mg / 20 ml. VIAL: 20ml. 1200 mg admin. as an IV infus. over 60 min. every 3 wks. until dis. progress. or unacceptab. toxicity. If the 1ST infus. is tolerated, all subsequent infus. may be delivered over 30 min. Do not administer atezolizumab as an IV push or bolus. See Lit.
Tmt. of pts. with local. advanced or metastat. urothelial carcinoma who are not eligible for cisplatin-contain. chemother. Tmt. of pts. with local. advanc. or metastatic urothelial carcinoma who have dis. progres. during or follow. any platinum-contain. chemother. or within 12 mnths. of neoadjuvant or adjuvant chemother. Tmt. of pts. with metastat. non-small cell lung cancer (NSCLC) who are naïve to anti-PD-L1 or anti-PD-1 therap. and have dis. progress. during or follow. platinum-contain. chemother. Pts. with EGFR or ALK genomic tumor aberrations should have dis. progress. on approv. ther. for these aberrations prior to receiving atezolizumab.